Skip to content
SABCS logo

SABCS

19 interviews

San Antonio Breast Cancer Symposium

Interviews and expert commentary from SABCS — study authors and key opinion leaders discuss the findings and their clinical implications.

Adding Anthracycline Improved Outcomes for Patients with High-Risk HR-positive, HER2-negative Breast Cancer

Adding Anthracycline Improved Outcomes for Patients with High-Risk HR-positive, HER2-negative Breast Cancer

SAN ANTONIO, USA—Women with hormone receptor positive HER-2 negative breast cancer and Oncotype DX recurrence scores above 31 could benefit from having anthracycline therapy added to their taxane-base

28 March 2025
8 min
Bilateral Mastectomy and Salpingo-Oophorectomy Significantly Extend Survival In BRCA-mutation Carriers Who Already Have Breast Cancer

Bilateral Mastectomy and Salpingo-Oophorectomy Significantly Extend Survival In BRCA-mutation Carriers Who Already Have Breast Cancer

Bilateral Mastectomy and Salpingo-Oophorectomy Significantly Extend Survival In BRCA-mutation Carriers Who Already Have Breast Cancer The important question of whether to recommend risk-reducing surge

26 February 2025
13 min
E. Shelley Hwang MD MPH: Randomized Study Found Surgery-Sparing Active Monitoring Safe in Patients With Low-risk DCIS

E. Shelley Hwang MD MPH: Randomized Study Found Surgery-Sparing Active Monitoring Safe in Patients With Low-risk DCIS

SAN ANTONIO, USA—In patients with hormone receptor-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS) active monitoring, compared with surgery, resulted in no difference in terms of can

16 January 2025
14 min
AUDIO JOURNAL OF ONCOLOGY: Safe to Spare Post-Mastectomy Chest Wall Radiotherapy in Most Patients with Intermediate Risk Breast Cancer

AUDIO JOURNAL OF ONCOLOGY: Safe to Spare Post-Mastectomy Chest Wall Radiotherapy in Most Patients with Intermediate Risk Breast Cancer

SAN ANTONIO, USA—There was no benefit from chest wall irradiation in patients who had intermediate-risk breast cancer, according to findings reported at the 2024 San Antonio Breast Cancer Symposium fr

11 January 2025
15 min
Younger than 35 with breast cancer: always consider neoadjuvant chemotherapy

Younger than 35 with breast cancer: always consider neoadjuvant chemotherapy

SAN ANTONIO, TEXAS—Women with breast cancer under the age of 35 respond very well to neo-adjuvant chemotherapy as the first line of attack against their disease, according to research from the German

18 December 2012
Local or regional breast cancer recurrences mandate adjuvant chemotherapy

Local or regional breast cancer recurrences mandate adjuvant chemotherapy

SAN ANTONIO, TEXAS—Patients with local or regional recurrences of breast cancer, should be treated with chemotherapy as well as surgery and

11 December 2012
Breast cancer: less radiotherapy in fewer hospital visits is just as good for preventing relapse

Breast cancer: less radiotherapy in fewer hospital visits is just as good for preventing relapse

SAN ANTONIO, TEXAS—Three weeks of radiotherapy rather than five — and lower overall doses of radiation — were just has as effective for treating breast cancer in the UK START trial conducted among 445

11 December 2012
Audio Journal of Oncology in Advance – January 1st, 2007 – Reporting from San Antonio Breast Cancer Symposium, December 14-17, 2006

Audio Journal of Oncology in Advance – January 1st, 2007 – Reporting from San Antonio Breast Cancer Symposium, December 14-17, 2006

Dennis Slamon George Peoples James Holland Massimo Christofanilli Trastuzumab: Mature Results in Early Breast Cancer Show Superiority REFERENCE: San Antonio Breast Cancer Symposium 2006, Abstract: 52

2 January 2007
Audio Journal of Oncology 14.1, February 2006

Audio Journal of Oncology 14.1, February 2006

Reporting from: San Antonio Breast Cancer Symposium 2005 Scientific Editors: George Canellos, Dana-Farber Cancer Institute, Boston Gordon McVie, European Institute of Oncology, Milan Pat Price, Christ

9 January 2006
Non-Anthracyline Regimen May Be O.K. for Patients with Early Breast Cancer taking Trastuzumab (Herceptin)

Non-Anthracyline Regimen May Be O.K. for Patients with Early Breast Cancer taking Trastuzumab (Herceptin)

Dennis Slamon, UCLA School of Medicine, Los Angeles It may be reasonable to replace the anthracycline component of adjuvant chemotherapy with carboplatin in HER-2 positive patients with early breast c

11 December 2005